Experience of using bifren in idiopathic arterial hypotension in adolescent girls with vegetative-somatic disorders

Annotation. Idiopathic arterial hypotension (IAH) is a common pathological condition among adolescent girls, often accompanied by multisystem functional changes against a background of excessive anxiety, which can subsequently lead to serious consequences such as arterial hypertension, cerebrovascular disorders, pregnancy complications, and others. The aim of this study is to assess the impact of the anxiolytic Bifren on comorbid psychosomatic complaints in female students with IAH and excessive anxiety. Materials and methods. The study involved 32 female students aged 18-24, diagnosed with IAH. They were divide into two groups: the main group (n=18) and the control group (n=15). The main group presented with excessive anxiety, assessed using the Spielberger-Hanin scale. Comorbid vegetative-somatic symptoms were identify through standardized Lewis testing. Autonomic regulation was assesse using heart rate variability parameters. The main group received Bifren therapy at a daily dose of 250-500 mg for 3-4 weeks, after which a follow-up survey was conduct to evaluate the treatment's effectiveness. The control group consisted of girls with chronically low blood pressure who did not exhibit subjective symptoms or excessive anxiety. Results: Bifren therapy reduced excessive anxiety symptoms in 77.78% of cases. However, its effect on other comorbid symptoms, such as asthenia, dizziness, and cardiac symptoms, was less pronounce. The positive treatment outcomes in most patients were short-lived. Conclusions: The anxiolytic Bifren demonstrated effectiveness in reducing excessive anxiety in patients with IAH, though its impact on comorbid multisystem symptoms was less significant. This underscores the need for a comprehensive approach to treating multisystem functional changes in IAH due to the complexity of regulatory neurovegetative mechanisms involved in adaptation to external stimuli.